登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C30H45NO7P · Na
化学文摘社编号:
分子量:
585.64
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
产品名称
福辛普利 钠, ≥98% (HPLC), powder
InChI
1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1
SMILES string
O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]
InChI key
TVTJZMHAIQQZTL-TXDYNIFHSA-M
assay
≥98% (HPLC)
form
powder
storage condition
desiccated
color
white to off-white
solubility
H2O: >20 mg/mL
originator
Bristol-Myers Squibb
storage temp.
−20°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
相关类别
Features and Benefits
This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Biochem/physiol Actions
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor.
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.
General description
Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.
signalword
Warning
hcodes
Hazard Classifications
Eye Irrit. 2 - Repr. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Disposition of fosinopril sodium in healthy subjects
Singhv SM, et al.
British Journal of Clinical Pharmacology, 25(1), 9-15 (1988)
S Giovannini et al.
The journal of nutrition, health & aging, 14(6), 457-460 (2010-07-10)
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial
Ya-chen Zhang et al.
Cell biochemistry and biophysics, 64(3), 205-211 (2012-06-26)
Fosinopril, an angiotensin-converting enzyme inhibitor, is known to attenuate cardiomyopathy induced by doxorubicin (DOX); however, the mechanisms of this cardioprotection are not fully elucidated yet. In the present study, experimental cardiomyopathy was induced in rats by administration of DOX with
Dinesh Shrikrishna et al.
Chest, 146(4), 932-940 (2014-02-22)
Skeletal muscle impairment is a recognized complication of COPD, predicting mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in control of muscle phenotype. We hypothesized that angiotensin-converting enzyme (ACE) inhibition would improve quadriceps function and exercise performance in
Patrick Rossignol et al.
Hypertension (Dallas, Tex. : 1979), 60(2), 339-346 (2012-07-11)
Optimal blood pressure (BP) targets are still controversial in end-stage renal disease. Recent data have highlighted shortcomings of the usual BP hypothesis in other patient populations and emphasized the importance of visit-to-visit variability of BP in predicting cardiovascular events. The
商品
We offer many products related to angiotensin receptors for your research needs.
Discover Bioactive Small Molecules for ADME/Tox
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
